March 23, 2016 SOURCE: REGEN BIOPHARMA INC.

Regen BioPharma, Inc. Submits IND Application to FDA on tCellVax, a Checkpoint Inhibitor for Cancer Therapy. New approach uses siRNA to silence NR2F6 activity in human immune cells.